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ABSTRACT
Recent studies revealed that the herb Andrographis paniculata
possesses cardioprotective activities. Using neonatal rat cardi-
omyocytes, the cardioprotective actions of several diterpene
lactones derived from A. paniculata including andrographolide,
14-deoxyandrographolide, 14-deoxy-11,12-didehydroandrogra-
pholide, and sodium 14-deoxyandrographolide-12-sulfonate were
investigated. Pretreatment with andrographolide but not with the
other compounds protected the cardiomyocytes against hypoxia/
reoxygenation injury and up-regulated the cellular-reduced gluta-
thione (GSH) level and antioxidant enzyme activities. The cardio-
protective action of andrographolide was found to coincide in a
time-dependent manner with the up-regulation of GSH, indicating
the important role of GSH. The cardioprotective action of an-
drographolide was also completely abolished by buthionine
sulfoximine, which acts as a specific -glutamate cysteine li-
gase (GCL) inhibitor to deplete cellular GSH level. It was sub-
sequently found that the mRNA and protein levels of the GCL
catalytic subunit (GCLC) and modifier subunit (GCLM) were
up-regulated by andrographolide. Luciferase reporter assay
also demonstrated that andrographolide activated both the
GCLC and the GCLM promoters in the transfected rat H9C2
cardiomyocyte cell line. The 12-O-tetradecanoylphorbo-13-ac-
etate response element or the antioxidant response element
may be involved in the transactivating actions of andrographol-
ide on the GCLC and GCLM promoters. The present study
pinpoints andrographolide as a cardioprotective principle in A.
paniculata and reveals its cytoprotective mechanism.
Andrographis paniculata (Burm. f.) Nees (Acanthaceae)
(AP) is an herb originated from India and widely distributed
in southern China. It has been used in traditional systems of
medicine to treat a number of ailments including common
cold, fever, diarrhea, liver diseases, and inflammation (World
Health Organization, 2002). Recent studies have revealed
some cardiovascular effects of this herb (Zhang and Tan,
1996; Thisoda et al., 2006). The crude extract of AP (Guo et
al., 1995) and its flavonoid fraction API0134 (Guo et al.,
1996) have been shown to protect dog hearts against isch-
emia/reperfusion. However, the active components in this
herb and the mechanism of these cardioprotective actions
remain obscure.
Using a primary neonatal rat cardiomyocyte (NRC) model,
we have screened a number of medicinal materials used in
traditional Chinese medicine for their cardioprotective ac-
tions. Our screening results indicated that pretreatment
with a crude extract of AP could protect NRCs from hypoxia/
reoxygenation (H/R) damage. However, the protective action
of AP cannot be explained by the presence of antioxidants in
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the herb as might have suggested by previous studies (Guo et
al., 1995, 1996). This is because in our established H/R pro-
tocol (Woo et al., 2005), the pretreatment followed by a wash-
ing step removes any drug carried over from the pretreat-
ment and thus eliminates any direct antioxidant effect
during H/R. In addition, the active cardioprotective ingredi-
ent in AP is unknown. Thus, we performed our screening
assay on a number of selected compounds derived from AP,
including its major component, the diterpene lactone androgra-
pholide (I) and two of its closely related derivatives, 14-deoxyan-
drographolide (II) and 14-deoxy-11,12-didehydroandrographol-
ide (III) (Medforth et al., 1990; World Health Organization,
2002) as well as sodium 14-deoxyandrographolide-12-sulfonate
(IV), a metabolite of andrographolide that has been prepared as
a pharmaceutical agent (He et al., 2003) (see Fig. 1 for the
structures of the compounds). Our results suggested that the
cardioprotective action of AP could be attributed to androgra-
pholide. The present report describes the cardioprotective ac-
tion of this compound and its mechanism of action.
Materials and Methods
Animals. The protocols related to animal studies have been ap-
proved by the Animal Research Ethics Committee, The Chinese
University of Hong Kong. The rats were bred and maintained in the
Laboratory Animal Service Center of The Chinese University of
Hong Kong.
Materials. The compounds used in the present investigation were
of analytical quality with a minimum purity of 98%. Andrographol-
ide (I) was obtained from Sigma-Aldrich (St. Louis, MO). 14-De-
oxyandrographolide (II) and 14-deoxy-11,12-didehydroandrographol-
ide (III) were supplied by LKT Laboratories (St. Paul, MN). Sodium
14-deoxyandrographolide-12-sulfonate (IV) was purchased from the
Kang Da Pharmaceutical Research Institute of West China Univer-
sity of Medical Science (Chengdu, Sichuan, China). Stock solutions of
the compounds at 20 mM in dimethyl sulfoxide (for compounds I–III)
or water (for compound IV) were prepared, appropriately diluted,
and added to the cell culture media. All other reagents were of the
highest analytical grade available.
Culture of NRCs and Cell Line. NRCs were isolated from
Sprague-Dawley rats 1 to 2 days after birth and cultured in DMEM/
medium 199 4:1 medium with 0.1% insulin-transferrin-selenium G
supplement (Invitrogen, Carlsbad, CA), 0.5% horse serum, and 0.3%
penicillin-streptomycin as described previously (Woo et al., 2005).
The rat cardiomyocyte cell line H9C2 (ATCC CRL-1446, passage
6–10; American Type Culture Collection, Manassas, VA) was main-
tained in DMEM with 10% fetal bovine serum and induced to express
the myotube phenotype by changing the culture medium to DMEM
with 2% horse serum and 0.3% penicillin-streptomycin 14 days be-
fore the transfection experiment.
NRCs Subjected to H/R Injury. The cultured NRCs were pre-
treated with the test compounds or the control vehicle. After the
preincubation period, the culture medium was removed, and the cells
were washed with a washing buffer (5 mM HEPES, 137 mM NaCl, 4
mM KCl, 1 mM MgCl2, 1.5 mM CaCl2, pH 7.0). The cells were then
incubated in an acidic glucose-free DMEM base medium and further
subjected to 10 h of hypoxia (oxygen level, 0.5%) followed by 1 h of
reoxygenation in DMEM as described previously (Woo et al., 2005).
Lactate Dehydrogenase Assay. Lactate dehydrogenase (LDH;
EC 1.1.1.27) leakage from cells is widely used as a marker of irre-
versible cell injury and necrotic cell death. LDH activities in the
hypoxia and the reoxygenation media as well as in the cell lysates
were analyzed by determining the rate of NADH oxidation in the
presence of pyruvate. The sum total of LDH activities in the hypoxia
and reoxygenation media as well as in the cell lysate obtained from
the same well would give the total LDH activity. The LDH released
during hypoxia or reoxygenation was expressed as a percentage of
the total LDH activity. The percentages of LDH released during
hypoxia and reoxygenation would be combined to give the percentage
of LDH released during H/R. The LDH assay has been shown in our
hands to give a higher discriminatory power of cell viability than
staining with propidium iodide or trypan blue (Woo et al., 2005).
Assays for Catalase, Superoxide Dismutase, Glutathione
Peroxidase, Glutathione Reductase, and Glutathione. Cul-
tured NRCs were washed twice with phosphate-buffered saline con-
taining 0.05 mM EDTA. Cell lysates were then obtained by sonica-
tion of the harvested cells. Antioxidant enzyme activities were
immediately assayed after brief centrifugation (800g for 5 min at
4°C) to obtain the supernatants. Catalase (EC 1.11.1.6) activity was
determined according to Aebi (1984). Superoxide dismutase (SOD;
EC 1.15.1.1) activity was determined by the nitroblue tetrazolium
method according to Beauchamp and Fridovich (1971). Glutathione
peroxidase (GPX; EC 1.11.1.9) activity was assayed using cumene
hydroperoxide as substrate (Lawrence and Burk, 1976). Glutathione
reductase (GR; EC 1.8.1.7) activity was assayed by the method of Aki
(2000). Oxidized glutathione (GSSG) and reduced glutathione (GSH)
were assayed immediately after sonication of the cells according to
the method of Anderson (1996). The enzyme activities and GSH
levels were normalized against the amount of protein present in the
samples as determined by the Lowry protein assay (Lowry et al.,
1951).
Real-Time PCR. Total RNA was extracted from the cultured
NRCs using TRIzol Reagent (Invitrogen) and reverse transcribed
using the Superscript First-Strand Synthesis System (Invitrogen).
To quantify the gene expression levels in the samples, real-time PCR
Fig. 1. Structures of diterpene lactones derived from A. paniculata. I, andrographolide; II, 14-deoxyandrographolide; III, 14-deoxy-11,12-didehy-
droandrographolide; IV, sodium 14-deoxyandrographolide-12-sulfonate.
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was performed on an ABI Prism 7700 Sequence Detection System
using SYBR Green PCR Master Mix (Applied Biosystems, Foster
City, CA) and primers specific for the catalytic or modifier subunits
of glutamate-cysteine ligase (GCL; EC 6.3.2.2) of rats; i.e., GCLC
(forward primer, 5-CTCTGCCTATGTGGTATTTG-3; reverse primer,
5-TTGCTTGTAGTCAGGATGG-3; amplicon size, 454 bp) and GCLM
(forward primer, 5-CTGACATTGAAGCCCAGGAG-3; reverse primer,
5-ACATTGCCAAACCACCACA-3; amplicon size, 270 bp) or primers
for -actin to normalize the amount of mRNA in the samples (forward
primer, 5-TCTTCCAGCCTTCCTTCC-3; reverse primer, 5-TAGAGC-
CACCAATCCACAC-3; amplicon size, 252 bp). The annealing temper-
ature and the primer concentrations were optimized for amplification
efficiency (amplification factors  1.90 for all the transcripts) after
validation of the dissociation curves and satisfactory separation of the
PCR products on a 2.5% agarose gel. The optimal thermal cycle protocol
for all the samples began with 10-min denaturation at 95°C, followed by
40 cycles of 95°C for 15 s, 62°C for 30 s, and 72°C for 45 s. The
concentrations of the primers used for GCLC, GCLM, and -actin were
200, 300, and 200 M, respectively. The relative amounts of mRNA for
GCLC and GCLM in the andrographolide-treated cells versus the ve-
hicle-treated control were calculated as the relative expression ratios in
comparison with -actin (Pfaffl, 2001).
Western Blot Analysis. Protein (50 g) from whole-cell lysates of
cultured NRCs was separated on a 10% SDS-polyacrylamide gel and
transferred onto a polyvinylidene difluoride membrane. Immuno-
blotting was carried out with polyclonal anti-GCLM antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) or polyclonal anti-GCLC anti-
body (Lab Visions, Suffolk, UK) or monoclonal anti--actin antibody
(Santa Cruz Biotechnology), followed by incubation with appropriate
secondary antibody coupled with horseradish peroxidase. The blot
was developed with a chemiluminescence system (Applied Biosys-
tems) according to the manufacturer’s protocol.
Electrophoretic Mobility Shift Assay. Cultured NRCs (1–2 
106 cells) were lysed by suspending the harvested cells in an ice-cold
hypotonic buffer containing 10 mM HEPES, pH 7.9, 10 mM KCl, 1.5
mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, and Complete pro-
tease inhibitor cocktail (at the concentration recommended by the
manufacturer; Roche Diagnostics, Indianapolis, IN) followed by mix-
ing with Nonidet P-40 (0.6% final concentration). The nuclear frac-
tion was obtained by centrifugation at 11,000g for 1 min. A hyper-
tonic buffer containing 20 mM HEPES, pH 7.9, 0.5 M NaCl, 1.5 mM
MgCl2, 0.1 mM EDTA, 25% glycerol, 1 mM dithiothreitol, and pro-
tease inhibitors was then added to the resuspended nuclei. Nuclear
extracts were obtained after further incubation for 30 min on ice and
removal of cell debris by centrifugation. To detect the binding of
nuclear proteins to the putative DNA sequences, electrophoretic
mobility shift assay (EMSA) was performed. Oligonucleotides were
synthesized, and the complementary strands were annealed before
their use as probes or competitors. The probes were prepared by 5
end labeling of double-stranded oligonucleotides with [-32P]ATP.
Binding reactions were carried out in a buffer containing 20 mM
Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM MgCl2, 0.5 mM EDTA, 1 mM
dithiothreitol, 10% glycerol, 0.3 mg/ml bovine serum albumin, and 50
g/ml double-stranded poly(dI-dC) with 6 g of nuclear extract at
4°C for 20 min. If unlabeled oligonucleotides (8 pmol) were used as
competitors, they were preincubated with the nuclear extract before
addition of the labeled probes (80 fmol). DNA-protein complexes
were separated on a 5% nondenaturing polyacrylamide gel in 0.5
Tris borate-EDTA buffer with 2.5% glycerol. Gels were dried on filter
paper and subsequently scanned on a PhosphorImager (Molecular
Imager FX; Bio-Rad Laboratories, Hercules, CA). The band intensi-
ties were quantified and compared by the built-in Quantity One 4.40
program (Bio-Rad Laboratories).
Luciferase Reporter Assay. Confluent cultures of differentiated
H9C2 cells in 24-well plates were transfected using Lipofectamine
reagent (Invitrogen) in a serum-free medium with recombinant plas-
mids (0.2 g) containing the human GCLC or GCLM promoters in
pGL3-basic vector (Promega, Madison, WI) (i.e., the 3802/GCSh5-
luc and 1927/GCSl5-luc in the original publications of Dr. Timothy
Mulcahy’s group (Mulcahy et al., 1997; Moinova and Mulcahy, 1998)
generously provided by Dr. Jeffrey Johnson, University of Wisconsin,
Madison, WI). Five hours after addition of the DNA-Lipofectamine
complexes, the serum-free medium was replaced with normal culture
medium containing different concentrations of andrographolide. Af-
ter a further incubation of 48 h, the cells were washed with phos-
phate-buffered saline and lysed by the passive lysis buffer (Pro-
mega). The lysates were centrifuged at 13,000g for 2 min at 4°C. The
resultant supernatants were saved for luciferase and protein assays.
Luciferase activity was determined by luminometry using a lucif-
erase reporter assay system (Promega).
Thiol Depletion Assay. Thiol depletion assay was performed
according to an established procedure (Jocelyn, 1987). The test com-
pound was incubated with GSH for 30 min in Tris-HCl with EDTA
buffer (0.1 M Tris-HCl, 1 mM EDTA, pH 8.5) at 37°C. The amount of
GSH before and after the incubation period was determined spectro-
photometrically using the thiol reagent 2,2-dipyridyl disulfide by
absorbance reading at 343 nm.
Statistical Analyses. All averaged results are presented as
mean  S.D. Statistical analyses were performed either with one-
way analysis of variance combined with Bonferroni’s transformation
to compare data among three or more groups or with the two-tailed
unpaired Student’s t test to compare two groups of data. A P value
0.05 was considered significant.
Results
Andrographolide Protects NRCs against H/R. Se-
lected diterpene lactones I to IV (Fig. 1) from AP were tested
for their protective actions on NRCs subjected to H/R dam-
age. LDH activities were used to indicate the extent of cellu-
lar damage in the NRCs. Preliminary studies indicated that
no observable difference could be noted in the viability (in
terms of cell number and LDH released) and the vital quality
(in terms of the morphological and functional characteristics
such as gap junction integrity and spontaneous contraction
rate) of the NRCs treated with the compounds at the highest
concentration tested versus the untreated control within the
treatment period examined. It was observed that NRCs sub-
jected to H/R insult resulted in an increase in LDH release.
The basal LDH release from control cardiomyocytes incu-
bated in unstressed condition was approximately 20% (Woo
et al., 2005). As shown in Fig. 2A, pretreating the cells with
andrographolide produced a dose-dependent decrease in the
amount of LDH release during H/R demonstrating a protec-
tive action of the compound. On the contrary, no protective
effects were observed in cells pretreated with the other diter-
pene lactones (Fig. 2, B–D).
Pretreatment but Not Cotreatment with Androgra-
pholide Affords Protection of NRCs. It was further in-
vestigated whether pretreatment (presence of the drug be-
fore, but not during, the stress regimen) or cotreatment
(presence of the drug during, but not before, the stress regi-
men) with andrographolide would result in different degrees
of protection. Figure 3 shows the results of the different treat-
ment regimens in the NRCs undergoing H/R. It can be seen that
pretreatment with andrographolide decreased LDH release by
approximately 21%. On the other hand, cotreatment with an-
drographolide during hypoxia afforded no observable protection
on the NRCs. This lack of protection during cotreatment was in
fact consistent with the results in which the presence of the
drug throughout the pretreatment and stress periods afforded
no additional protection compared with the situation in which
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the drug was present only during the pretreatment period.
These results imply that andrographolide might exert its car-
dioprotective effect via induction of some endogenous cellular
protective factors rather than acting directly.
Alteration in Antioxidant Status of NRCs Treated
with Andrographolide. To investigate whether androgra-
pholide exerts its cardioprotective actions through the en-
hancement of the antioxidant potential of the cardiomyo-
cytes, the activities of a number of antioxidant enzymes and
the GSH level in the NRCs treated with andrographolide or
its analogs were investigated under baseline condition. Re-
sults in Fig. 4 revealed that after treating the cardiomyocytes
with andrographolide for 3 days, the enzymatic activities of
SOD, catalase, GPX, and GR were increased by 21, 83, 27,


















































































Fig. 2. Andrographolide but not the other diterpene
lactones derived from AP protects cardiomyocytes from
H/R injury. NRCs in primary culture were pretreated
for 3 days with compounds I to IV (A–D), respectively,
at different concentrations shown. After washing, the
cells were subjected to H/R as described under Materi-
als and Methods. The percentage of LDH released dur-
ing H/R was determined. , P  0.001 compared with
the drug-free control (n  6).
Pretreatment + + – – + +
































Fig. 3. Pretreatment but not cotreatment with andrographolide affords
cardioprotection. NRCs in primary culture were divided into groups re-
ceiving different treatment regimens with C (control, white bars) or I (10
M andrographolide, dark bars): /, pretreatment for 3 days; /, no
pretreatment, cotreatment during hypoxia only; /, pretreatment for 3
days followed by cotreatment during hypoxia but not reoxygenation.
Percentage of LDH released during H/R was determined as described
under Materials and Methods. , P  0.001 compared with the control
in the same treatment group (n  6).
























Fig. 4. Changes in antioxidant status in NRCs treated with diterpene
lactones derived from AP. NRCs in primary culture were pretreated for 3
days with 10 M compounds I to IV. Vehicle controls were performed in
parallel. The amounts of SOD, catalase (CAT), GPX, GR, and GSH in the
lysates of the treated cells were measured as described under Materials
and Methods. , P  0.05 and , P  0.001 compared with the control
(n  5 or 6).
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and 99%, respectively. In addition, the cellular GSH level
was also increased to 258% of the control level. On the contrary,
after treating the cardiomyocytes with 14-deoxyandrographol-
ide, 14-deoxy-11,12-didehydroandrographolide, or sodium 14-
deoxyandrographolide-12-sulfonate, no significant increases in
antioxidant enzyme activities or GSH level were observed, cor-
roborating with the ineffectiveness of these compounds in pro-
tecting the NRCs against H/R damage (Fig. 2, B–D).
Effects of Andrographolide on the Antioxidant Sta-
tus and Cellular Resistance to H/R in NRCs: A Time-
Dependent Study. A time-dependent study of the effects of
andrographolide on the antioxidant enzyme activities and
the GSH level in cultured NRCs was performed. As shown in
Fig. 5A, no significant change could be observed in the activ-
ities of any of the antioxidant enzymes 12 h after treatment.
Induction of catalase and GR was evident 24 h after treat-
ment with andrographolide, and the degrees of induction
followed an increasing trend with time in general. The activ-
ity of catalase and GR reached 180 and 200% of the control,
respectively, after 88 h of treatment. Induction of SOD activ-
ity was observed 48 h after treatment, and the induction level
was approximately 130% of the control, which remained un-
changed until the end of the investigation period. Increase in
GPX activity was observed only after a prolonged period of
incubation (88 h) with andrographolide. On the other hand, a
significant increase in cellular GSH level (170%) could be
observed as early as 12 h after andrographolide treatment.
By 24 h, the GSH level had reached over 300% of the control,
after which the induction in GSH declines a little bit. A
time-dependent study of the protective action of androgra-
pholide on the NRCs against H/R was also performed. The
results in Fig. 5B show that a significant cardioprotective
effect could be observed as early as 12 h after pretreatment
with andrographolide. A gradual increase in the extent of
protection appeared as the pretreatment time increased to
33 h. Increase in the pretreatment duration beyond this point
seems to produce no additional protection.
Cardioprotective Action of Andrographolide Is Abol-
ished by a Cellular GSH Depletor. The results from the
time-dependent study show that cellular GSH level was up-
regulated as early as 12 h after treatment with androgra-
pholide, whereas no such effect could be observed in any of
the antioxidant enzymes. It is interesting to note that the
cardioprotective effect of andrographolide was also evident
12 h after treatment. Thus, it is deduced that the increase in
cellular GSH level may be responsible for the cardioprotec-
tive action of andrographolide. To substantiate this hypoth-
esis, buthionine sulfoximine (BSO), a specific GCL inhibitor,
was employed to deplete cellular GSH to see whether this
could abolish the cardioprotective action of andrographolide.
In addition, a specific catalase inhibitor, 3-amino-1,2,4-tria-
zole (ATA), was also used to see whether catalase may play a
role in the cardioprotective action of andrographolide. Pre-
liminary studies were conducted to determine the concentra-
tions and treatment periods of BSO and ATA that could bring
the andrographolide-induced GSH level or catalase activity
back to the control level. No cytotoxic effects of the inhibitors
could be observed at the concentrations used within the
treatment period. Figure 6A1 shows that treatment with 10
mM ATA for 90 min brought the increased catalase activity of
the andrographolide-treated NRCs back to the control level
and dramatically reduced the catalase activity in the un-
treated cells. However, the same treatment with ATA could
not abolish the cardioprotective effect of andrographolide
(Fig. 6A2; P  0.05 compared with I-blank). Cotreatment
with 0.15 mM BSO during the last 8 h of the pretreatment
period brought the increased cellular GSH level of the an-
drographolide-treated cardiomyocytes back to the control
level and dramatically reduced the GSH level in the un-
treated cells (Fig. 6B1). The same treatment with BSO com-
pletely abolished the cardioprotective effect of andrographol-
ide (Fig. 6B2; P  0.05 compared with C-blank), suggesting
the pivotal role of GSH in the cardioprotective effect of an-
drographolide. The inverse correlation between the cellular
GSH level and the cardioprotective action was also substan-
tiated in the elevation of LDH release during H/R in the
BSO-treated control (Fig. 6B2; P  0.001 compared with
C-blank).
Induction of GCL Subunits mRNA and Protein Lev-







































































































Fig. 5. Time-dependent changes in antioxidant status and resistance to
H/R injuries in NRCs treated with andrographolide. NRCs in primary
culture were treated with control vehicle or 10 M andrographolide for
different duration as indicated. The levels of SOD (E), catalase (CAT) (F),
GR (‚), GPX (Œ), and GSH () in the resultant cell lysates were deter-
mined as described under Materials and Methods. The amounts of ana-
lytes in the andrographolide-treated cells were expressed as a percentage
of the control in each case (A). In another set of experiments, the an-
drographolide- or vehicle-pretreated cells were also subjected to H/R as
described under Materials and Methods. The percentages of LDH re-
leased during H/R from the cells pretreated with C (control vehicle, white
bars) and I (andrographolide, dark bars) were determined (B). , P  0.05,
, P  0.01, and , P  0.001 compared with control (n  6).
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results indicated that the GSH/GSSG ratio in andrographol-
ide-treated NRCs had little difference from that of the un-
treated cells, suggesting that the increase in GSH level is the
result of an increase in de novo GSH synthesis rather than an
increased recycling of GSSG. GSH is synthesized intracellu-
larly by the consecutive action of GCL and glutathione syn-
thase (EC 6.3.2.3) in which the GCL-catalyzed reaction is the
rate-limiting step. Our results also indicated that cotreat-
ment with the GCL inhibitor BSO reduced the elevated GSH
level of the andrographolide-treated cardiomyocytes back to
the control level concomitant with abolition of the cardiopro-
tective action. Thus, it is hypothesized that andrographolide
induced GCL activity at an early stage of its action. There-
fore, real-time PCR and western blotting were performed to
quantify the mRNA and the protein expression levels of the
GCL subunits GCLC and GCLM, respectively. It was found
that the mRNA levels of GCLC and GCLM in NRCs were
induced as early as 2 h after treatment with andrographolide
(Fig. 7A). The induction in the mRNA level appeared to
plateau after 8 h (330% for GCLC and 480% for GCLM) and
remained 2-fold higher than the vehicle-treated control after
48 h. The results in the Western blot experiment (Fig. 7B)
demonstrated that the protein levels of GCLM and GCLC
also exhibited similar trends of induction by andrographol-
ide, with detectable changes as early as 4 h and maximal
responses of more than 3-fold induction at 12 and 48 h for
GCLM and GCLC, respectively (Fig. 7C). The kinetics of the
induction of the mRNA and the protein levels of GCLC and
GCLM by andrographolide match that of the increase in
cellular GSH level (Fig. 6A).
Transactivation of GCLC and GCLM Promoters by
Andrographolide. To study the actions of andrographolide
on GCLC and GCLM promoter/enhancer activities, luciferase
reporter assays were performed on the rat cardiomyocyte cell
line H9C2 transfected with the luciferase reporter construct
containing either the human GCLC promoter or the GCLM
promoter. The results show that both the GCLC and GCLM
promoter/enhancer activities in the transfected cells were
increased after incubation with andrographolide (5 or 10
M), whereas no activation could be observed in cells trans-
fected with the empty pGL3-basic vector (Fig. 8).
Involvement of the 12-O-Tetradecanoylphorbo-13-
Acetate Response Element and Antioxidant Response
Element in the Andrographolide-Induced Activation
of GCLC and GCLM Genes. The real-time PCR results and
the luciferase reporter assay results suggest that androgra-
pholide induces the expression of GCL at the transcription
level. It was speculated that andrographolide might induce
the transcription of its target genes through activation of the
redox-sensitive or stress-induced transcription factors. EMSA
was therefore performed to investigate the possible involve-
ment of the following enhancer elements: B element [for the
binding of nuclear factor (NF)-B], 12-O-tetradecanoylphorbo-
13-acetate response element [TRE; for activator protein-1
(AP-1) binding], and antioxidant response element [ARE,
also known as electrophile response element; activated by
both the AP-1 family transcription factors and the NF-E2-
related factors (Nrfs)] (Dickinson et al., 2004) in the trans-
activation effects of andrographolide. Synthetic oligonucleo-
tides with the consensus sequences for the NF-B and AP-1
binding sites and the DNA sequences identified to be func-
tional AREs in the 5-flanking regions of the rat GCLC and
GCLM were labeled and used as probes (Table 1). The EMSA
results show that andrographolide significantly induced
AP-1 and ARE, but not NF-B responses (Fig. 9, A and B),
and the percentage of induction on AP-1 and ARE responses
seemed to be concentration-dependent, with a maximal re-
sponse of approximately 40% over the control at 10 M
andrographolide (Fig. 9B). It is interesting to note that the
induction effects of andrographolide appeared to be higher



















































































Fig. 6. Reversibility of the cardioprotective effect of
andrographolide: the different effects of ATA and BSO.
NRCs in primary culture were pretreated for 3 days
with control vehicle (C) or 10 M andrographolide (I).
The pretreated cardiomyocytes were subdivided into
two groups subjected to A, further treatment for 90 min
with plain medium (blank) or ATA (10 mM); or B,
cotreatment with BSO (0.15 mM) during the last 8 h of
the pretreatment period or sham treatments (blank)
performed in parallel as controls. Catalase activities
were then assayed for cells in treatment group A (A1),
and GSH levels were assayed in treatment group B
(B1). In another subset of study, the pretreated cells in
all these groups were also subjected to H/R for 8 h as
described under Materials and Methods, and the per-
centage of LDH released was determined for the respec-
tive groups (A2 and B2). , P  0.001 and #, P  0.05
compared with C-blank (n  4 for catalase; n  5 for
GSH; n  6 for LDH).
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for GCLM-ARE1 than for GCLC-ARE4 at the two concentra-
tions tested, corroborating with the higher induction effect of
andrographolide on GCLM mRNA at 8 h (Fig. 7A).
Andrographolide Reacts with Thiols. We hypothesize
that the induction of GCL by andrographolide is a cellular
defense mechanism triggered out of a perceived adverse effect of
andrographolide toward the redox status of the cardiomyocytes.
We have thus tested whether andrographolide and other diter-
pene lactones could deplete GSH. GSH (50 M) was incubated
with compounds I to IV (100 M) or with the positive control
N-ethylmaleimide in Tris-HCl with EDTA buffer for 30 min,
and then the amount of GSH remained was determined and
expressed in terms of the background subtracted absorbance at
343 nm (A343). It was found that andrographolide depleted GSH
in this in vitro reaction system (with the A343 value determined
to be 0.310 versus 0.350 for the control). The reactivity of an-
drographolide toward GSH was low considering that approxi-
mately 90% of GSH still remained after 30 min of reaction.
Nevertheless, the thiol-depleting effect of andrographolide is
unambiguous because no significant reaction was observed be-
tween GSH and the other diterpene lactones, II to IV (A343
values were determined to be 0.348–0.349). All the diterpene
lactones tested were found to be stable under the experimental
condition because the UV spectra of the solutions immediately
after preparation were identical to those after incubation (data
not shown).
Discussion
The anti-ischemic action of AP extracts has been attributed
to the alleviation of calcium overload and the scavenging of
Treatment time (h) 







































































Fig. 7. Andrographolide increases the mRNA and the protein expression
levels of GCL subunits in cardiomyocytes. A, relative mRNA expression
levels of GCLC and GCLM in cardiomyocytes treated with andrographolide.
NRCs in primary culture were treated with control vehicle or andrographol-
ide (10 M) for different durations as indicated. Total RNA of the treated
cells was extracted and reverse transcribed. The amounts of mRNA for
GCLC, GCLM, and -actin in each sample were quantified by real-time
PCR. The relative mRNA levels for GCLC (dark bar) and GCLM (white bar)
in the andrographolide-treated cells were calculated as described in the text
and expressed as percentages of control in six observations. Error bars,
S.D.s. B, representative immunoblot depicting the protein expression levels
of GCLC, GCLM, and -actin in the total cell lysates of NRCs treated with
andrographolide (10 M) for different durations as indicated. C, average
data on GCLC and GCLM protein expression levels in NRCs treated with
andrographolide. Data are presented as percentages of control (n  4). , P 
0.05, , P  0.01, and , P  0.001 compared with control.
pGL3-hGCLC





































Fig. 8. Andrographolide activates GCLC and GCLM promoters. H9C2
cells were transfected with the pGL3-hGCLC-luciferase construct, the
pGL3-hGCLM-luciferase construct, or the pGL3-basic vector and then
treated with control vehicle or andrographolide (5 or 10 M) for 48 h. The
levels of activation of the transgenes were determined by quantifying the
luciferase reporter activity in terms of relative luminescence units
(RLUs) after normalization with the protein concentrations of the cell
lysates as described under Materials and Methods. , P  0.05 and ,
P  0.001 compared with control (n  6).
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free radicals during myocardial ischemia-reperfusion (Guo et
al., 1995, 1996). However, a major difference of the current
study from these previous studies is that pretreatment but
not cotreatment with andrographolide produces the protec-
tive action on the cardiomyocytes (Fig. 3). Therefore, our data
indicate that the observed cardioprotective effect (Fig. 2A)
cannot be attributed to a direct free radical scavenging effect
of andrographolide. Protection by pretreatment with androgra-
pholide must act via other mechanisms. We have therefore
explored the possibility that andrographolide could produce its
cardioprotective action by altering the antioxidant status of the
cultured cardiomyocytes.
Treatment with AP extracts has been shown to increase
the antioxidant enzyme activities as well as the cellular
nonprotein thiol levels in vivo (Singh et al., 2001; Trivedi and
Rawal, 2001). Our data (Fig. 4) clearly show that this up-
regulation in antioxidant enzyme activities and GSH level
can also be demonstrated in vitro on NRCs and that an-
drographolide is the active component in this herb responsi-
ble for this action. The ineffectiveness of other diterpene
lactones in inducing these effects suggests that the cellular
antioxidant-enhancing action of andrographolide is specific
to its chemical structure. It also indicates a causal link be-
tween the enhancement of the cellular antioxidant potential
and the observed cardioprotective effect of andrographolide.
The results of the time-dependent (Fig. 5) and inhibitor
(Fig. 6) studies demonstrate that increased cellular GSH level is
responsible for the cardioprotective action of andrographolide.
The glutathione antioxidant system is crucial for reactive oxy-
gen species (ROS) defense in the heart. GSH directly detoxifies
ROS and repairs ROS-induced damage by scavenging free rad-
icals. In addition, GPX detoxifies a wide variety of ROS at the
expense of GSH. GSH also plays an important role in maintain-
ing protein thiol groups, tocopherol, and ascorbate of the cells in
reduced states. Thus, the up-regulation of GSH level by more
than 2-fold would undoubtedly enhance the antioxidant defense
against subsequent oxidative damage during H/R in the an-
drographolide-treated NRCs. The observed induction of GR by
andrographolide in concert with the up-regulation of GSH (Fig.
5A) may also contribute a part in alleviating the oxidative
stress during H/R because GR is important in recycling GSSG
back to GSH.
TABLE 1
Sequence information of DNA probes for detecting NF-B, AP-1, and ARE responses
The core sequences for NF-B, AP-1, and ARE sites are indicated in capital letters. Underlined nucleotides indicate the AP-1- or TRE-like sequence. In the AP-1 probe, the
nucleotides “ca” in italics replace the original nucleotides “gc” in the Promega sequence because the original sequence represents a full ARE. The ARE sequences are taken
from the rat genome sequences at the indicated positions upstream of the transcription start sites of the GCLC and GCLM genes, respectively. They were chosen by comparing
the 5-flanking regions of the rat GCLC and GCLM genes with those of the human ones such that the excerpted ARE-like sequences corresponded to the functional enhancer
elements GCLC-ARE4 (Mulcahy et al., 1997) and GCLM-ARE1 (Moinova and Mulcahy, 1998) in human. It was noted that although the presence of the TRE-like sequence
in ARE is conserved between human and rat, the TRE in rat GCLC-ARE4, unlike the human counterpart, is external of the ARE core sequence.
Specificity Sequence Source of Information
NF-B agttgagGGGActTTCCcaggc Promega
AP-1 cgcttgaTGAGTCAcacggaa Promega (modified)
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Fig. 9. Andrographolide induces AP-1 and ARE but not NF-B responses in cardiomyocytes. NRCs in primary culture were treated with 5 or 10 M
I (andrographolide) or control vehicle for 8 h, followed by incubation of the resultant nuclear extracts with the respective probe (radiolabeled
oligonucleotides shown in Table 1). The DNA-protein complexes formed were analyzed by EMSA as described under Materials and Methods. A, gel
image of a typical experiment. The positions of the gel-band(s) corresponding to the DNA-protein complexes of interest (arrows) were identified in
preliminary experiments using competitor techniques. B, summary of the results in A based on digital autoradiographic values generated by the
Quality One program over three independent experiments. , P  0.05 and , P  0.01 compared with the respective vehicle-treated control.
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In a recent study on H9C2 cells (Seo et al., 2004), pretreat-
ment with a low dose of hydrogen peroxide (H2O2) was found
to induce an adaptive tolerance toward a subsequent chal-
lenge with a lethal concentration of H2O2. It was subse-
quently shown that the increase in GSH content rather than
catalase activity was responsible for the adaptive response
because the tolerance to H2O2 could be completely abolished
by BSO but not by ATA. Likewise, the increase in GSH
content was attributed to an increased GCL activity in the
H2O2-pretreated cells. Using an H/R model in the present
investigation, we have also demonstrated the important role
of GSH in the preconditioning effect of andrographolide in
NRCs. Taken together, these results support the notion that
increasing GSH synthesis is one of the most crucial mecha-
nisms for cardiomyocytes to guard against oxidative stress.
The redox-dependent regulation of GSH synthesis is con-
trolled by the induction of the GCL transcripts. The expres-
sion of these genes is governed by a number of enhancer
elements in their promoters, in particular the B element,
TRE, and ARE are redox-sensitive and have been shown to be
activated by a number of chemicals and stresses (Rahman
and MacNee, 2000; Dickinson et al., 2004). Our EMSA re-
sults (Fig. 9) suggest that the transactivation effects of an-
drographolide on the GCLC and GCLM genes (Figs. 7 and 8)
may involve AP-1 and ARE but not NF-B. The present data
provide evidence that andrographolide may induce the GCL
subunit genes through TRE and/or ARE activation. An-
drographolide has been suggested to interfere with the bind-
ing of NF-B to DNA, probably through its interaction with
cysteine 62 of p50 subunit (Xia et al., 2004). This effect was
not observed in NRCs in the present investigation, presum-
ably because the initial NF-B response was a basal one and
had not been induced to a high level by any stimulatory agent
as in the case of other studies.
ARE is present in the promoter regions of various genes
encoding for phase II detoxification enzymes and antioxidant
enzymes (Nguyen et al., 2003). The transcription factor Nrf-2
is believed to be essential for the positive regulation of ARE-
mediated gene expression (Nguyen et al., 2003; Jaiswal,
2004). In addition, other transcription factors such as Jun
(c-Jun, Jun-D, and Jun B), c-Fos, Fra-1, small Maf (MafG,
MafK, and MafF), and Nrf-2 may heterodimerize to regulate
ARE-mediated transcription (Venugopal and Jaiswal, 1996;
Jardine et al., 2002; Jaiswal, 2004). The transcription factors
involved in the andrographolide-induced activation of TRE
and ARE are presently unknown. Further studies to identify
these transcription factors are highly warranted.
Talalay et al. (1988) have systemically characterized the
ability of various chemicals in inducing the ARE-driven
NAD(P)H/quinone oxidoreductase (NQO; EC 1.6.99.2) in
Hepa1c1c7 cells. These authors concluded that the potencies
of these chemicals in inducing NQO activity are dependent
on their Michael reaction chemistry and specifically 2-meth-
ylene-4-butyrolactone (the lactone ring structure resembles
that in andrographolide, Fig. 10A) would be 10 times more
potent than -crotonolactone (resembles that in 14-deoxyan-
drographolide, Fig. 10B) in inducing NQO. It was further
proposed that the inducers of ARE being Michael reaction
acceptors with the ,-unsaturated ketone moieties may in-
teract with the sulfhydryl groups of a number of cysteine
residues on the cytosolic redox sensor recently identified to
be Kelch-like ECH-associated protein 1 with concomitant
release and activation of the transcription factor Nrf2 (Din-
kova-Kostova et al., 2002; Wakabayashi et al., 2004). It is
conceivable from the chemical structures (Fig. 1) that the
,-unsaturated ketone moiety is present in all the diterpene
lactones investigated in the present study. In addition, the
presence of an allylic hydroxyl group at C14 of andrographol-
ide significantly increases the electrophilicity of C12 and
facilitates addition reaction with thiols. The reaction mech-
anism of nucleophilic attack on this electrophilic carbon (pro-
posed in Fig. 10C) explains our observation that androgra-
pholide gradually depletes GSH in a weak alkaline solution.
This result is in line with our observation that andrographol-
ide treatment induces rather than depletes cellular GSH
because the reactivity of andrographolide toward different
cellular thiols is heterogeneous. At cellular pH, the reaction
between andrographolide and GSH is expected to be very
slow. It could be deduced from nucleophilic addition reaction
chemistry that basic amino acid residues present in close
proximity with the reactive cysteine residues in certain cys-
teine-bearing redox-sensitive signaling molecules would fa-
vor the interaction between andrographolide and the free
cysteine residues on these proteins. Thus, it would be inter-
esting to see whether andrographolide may trigger its vari-
ous cellular effects through interaction with redox sensors
such as Kelch-like ECH-associated protein 1. It is noteworthy
that 14-deoxy-12-(cysteine-S-yl)-andrographolide-3-O-sul-
fate, a metabolite of andrographolide resembling the nucleo-
philic addition product of cysteine on C12 of andrographolide,
has recently been isolated from human urine (Cui et al.,
2004).
Epidemiological and clinical studies on the potential ben-
efits of antioxidant supplementation in the prevention of
cardiovascular disease and cancer have come up with ambiv-
alent results (Dutta and Dutta, 2003). On the contrary, an-
tioxidants from natural sources have consistently been
shown to produce beneficial effects (Rietveld and Wiseman,
2003; Zern and Fernandez, 2005). Consumption of these nat-
ural antioxidants is believed to improve the overall antioxi-
dant status of the body and protect the body against the toxic
effects of free radicals. Recent research focus has also shifted
toward means that could augment endogenous antioxidant
potential because this is expected to offer better protection
against oxidative stress than the exogenously administered
antioxidants themselves. As a matter of fact, studies on the
chemopreventive effects of broccoli and other cruciferous veg-
etables on cancer have entered preclinical and clinical phases
(Clapper et al., 1997; Kensler et al., 2000; Park and Pezzuto,
Fig. 10. A, structure of 2-methylene-4-butyrolactone. B, structure of
-crotonolactone. C, nucleophilic attack on andrographolide. Only the
butyrylactone moiety of andrographolide is shown.
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2002). The phase II enzyme-inducing effects and the protec-
tive effects against oxidative DNA damage form the pharma-
cological basis of the chemopreventive activities of these
botanicals.
AP is an herb with a long history of therapeutic usage in
Oriental and Indian medicine (World Health Organization,
2002). It has low toxicity in human (Coon and Ernst, 2004)
and exhibits significant beneficial effects on the cardiovascu-
lar system (Guo et al., 1995, 1996; Thisoda et al., 2006).
Andrographolide is identified to be responsible for the en-
hancement of the cellular antioxidant defense in the present
study. Thus, AP would be a useful remedy in pathological
conditions, with increased oxidative stress such as ischemia/
reperfusion injury or free radical-induced tissue injury
(Trivedi and Rawal, 2001).
The finding that some analogs of andrographolide could be
totally inactive has important implications because there are
recent concerns regarding the stability of diterpene lactones.
Andrographolide has been reported to gradually convert to
14-deoxy-11,12-didehydroandrographolide during storage,
and this process is accelerated by heat (Lomlim et al., 2003).
Thus, preservation of the andrographolide content during the
drug manufacturing and storage process is of utmost impor-
tance to prevent the loss of the biological activity of AP.
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